Ofatumumab
Ofatumumab
Definition
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.
Also known as Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, OFATUMUMAB — per NCIT
Also identified as
- ATC L01FA02 per RXNORM
- ATC L04AG12 per RXNORM
- NCIT NCIT:C66952 per NCIT
- SCTID 444607009 per RXNORM
- SCTID 444609007 per RXNORM
- SCTID 895672000 per RXNORM
- UNII M95KG522R0 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Lymphoid leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.